查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1933908

系统性自体发炎性疾病治疗药物市场（依药物类别、作用机转、给药途径、通路及最终使用者划分）－全球预测，2026-2032年

Systemic Autoinflammatory Diseases Drug Market by Drug Class, Mechanism Of Action, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，系统性自体发炎性疾病治疗市场价值将达到 10.4 亿美元，到 2026 年将成长至 11.2 亿美元，到 2032 年将达到 18.2 亿美元，复合年增长率为 8.24%。

关键市场统计数据
基准年 2025 10.4亿美元
预计年份：2026年 11.2亿美元
预测年份 2032 18.2亿美元
复合年增长率 (%) 8.24%

本书权威地介绍了用于治疗系统性自体发炎性疾病的药物，重点阐述了当前临床挑战、诊断障碍以及指导药物研发和相关人员参与的策略要务。

系统性自体发炎性疾病的治疗是一个不断发展的前沿领域，其特征是临床表型多样、诊断路径复杂，且存在从症状管理到长期缓解疾病等诸多未满足的需求。这种现状促使药物研发人员、临床医生和支付方提出了一系列多学科需求，包括加速开发可靠的诊断演算法、完善分层治疗方案，以及使临床试验终点与有意义的、以患者为中心的疗效指标相一致。这些因素凸显了在新型药物和仿单标示外用药的整个生命週期中整合证据产生的重要性。

深入分析了改变系统性自体发炎性疾病领域的科学、监管和商业性变化，以及加速在整个治疗过程中采用新治疗方法的趋势。

系统性自体发炎性疾病领域正经历着变革性的转变，这一转变涵盖了科学发现、监管环境和商业性应用等各个面向。细胞激素生物学的进展以及对不同发炎路径检验的验证，已将白细胞介素-1、白细胞介素-6、Janus激酶和肿瘤坏死因子-α等靶点从实验候选药物转变为临床可操作的机制。这些科学发现有助于更精准地对患者进行分层，并为联合治疗和序贯疗法开闢了道路，从而能够同时应对急性加重和慢性发炎。

评估2025年美国累积关税对治疗系统性自体发炎性疾病药物生产商的供应链、定价和跨境商业策略的影响

2025年，美国关税政策的累积变化为系统性自体发炎性疾病治疗药物的全球供应链环境引入了新的变数，影响了价值链上各相关人员的采购、分销和定价策略。製造商正在重新评估其采购基础并实现供应商多元化，以降低关税风险，同时确保对温度敏感的复杂生物製药和无菌注射剂的持续供应。这些调整凸显了区域製造能力和灵活的契约製造关係的重要性，因为它们能够吸收关税相关的成本波动。

关键细分洞察揭示了药物类别、作用机制、给药途径、分销管道和终端用户环境如何影响治疗策略和患者疗效。

清晰的细分为临床开发、商业化路径和患者需求提供了策略框架。检验不同药物类别之间的差异，我们发现白细胞介素-1抑制剂（如阿那白滞素、卡那单抗和Rilonacept）主要针对抑制自体发炎性疾病的急性发作，强调短间隔给药策略和减少急性治疗。Janus白细胞介素-6受体阻断剂（如沙拉利单抗和托珠单抗）则提供了一种靶向细胞激素的替代疗法，用于持续控制全身性发炎。 Janus激酶抑制剂（如Baricitinib、託法替尼和Upadacitinib）具有口服给药的优势，并有可能实现广泛的全身性免疫调节。同时，肿瘤坏死因子抑制剂（如Adalimumab、Etanercept和Infliximab）拥有丰富的真实世界安全性数据，是控制慢性发炎的重要对照药物。

区域洞察：识别美洲、欧洲、中东和非洲以及亚太市场在临床应用模式、支付方行为和监管细微差别方面的差异

区域趋势持续影响美洲、欧洲、中东和非洲以及亚太地区的研发和商业化策略，每个地区都有其独特的法规环境、支付者和临床应用环境。儘管美洲地区临床医生对生物製药有利于生物製剂的推广应用，但支付方的审查重点在于成本效益和能够证明其价值超越症状管理的真实世界疗效。从指南认可到获得广泛的支付方覆盖，需要强有力的卫生经济学证据和相关人员的积极参与，以期在降低急性医疗成本和减少长期併发症方面取得成效。

从策略层面深入分析领先生物製药开发公司的竞争定位、产品线重点、合作方式和商业化模式。

在系统性自体发炎性疾病治疗领域，各公司在药物发现、临床开发和商业化的各个阶段都制定了独特的策略方针。主要企业正投资于针对已验证的细胞激素路径的差异化科学和技术，同时积极拓展检验并探索联合用药策略，以最大限度地提高临床效益。竞争优势越来越依赖于进行头对头试验或真实世界比较研究，以证明新药相对于现有治疗方法的疗效、安全性和价值。

为行业领导者提供实用建议，以优化转化医学、监管和市场进入领域的研发优先排序、商业性执行和协作方式。

产业领导者可以采取多项有针对性的倡议，以促进系统性自体发炎性疾病治疗药物的研发、可及性和长期永续性。首先，应优先考虑基于生物标记的患者分层和适应性试验设计，以提高获得具有临床意义的终点指标的可能性，并促进与监管机构的对话。这种方法将缩短研发週期，并产生与临床医生和支付方直接相关的证据。其次，应投资于真实世界证据库和核准后研究，以证实药物的长期安全性和健康经济效益，从而提出更具说服力的报销提案。

一份透明的调查方法概述，详细介绍了资料来源、相关人员访谈、证据综合以及用于得出策略结论和见解的分析框架。

本研究将采用结构化、可重复的调查方法，整合一手与二手证据，兼顾研究深度与实际应用价值。资料来源包括同侪审查文献、监管文件、临床指南声明和匿名化的真实世界证据，并辅以对临床医生、支付者、製造商和供应链专业人员的访谈。所有证据均根据预先设定的纳入标准进行评估，以确保其具有时效性和临床有效性。

一份关于策略意义、持续挑战和优先行动的权威综合报告，供相关人员参考，以推进系统介导的自身发炎性疾病的治疗和商业性成功。

这些结论总结了相关人员在系统性自体发炎性疾病领域中应遵循的策略意义。科学进步已明确了可操作的靶点，并拓展了治疗选择，但要实现持续的临床应用，还需要在实际应用环境中，在对照试验之外，获得更多证据。监管和报销环境正在不断演变，更加重视可验证的价值和适应性证据的生成，这要求各方共同投资于核准后数据和相关人员。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 系统性自体发炎性疾病治疗市场（依药物类别划分）

  • IL-1抑制剂
    • 阿纳金拉
    • 卡那单抗
    • Rilonacept
  • 白细胞介素-6受体阻断剂
    • Sarilumab
    • 托珠单抗
  • JAK抑制剂
    • Baricitinib
    • 託法替尼
    • Upadacitinib
  • TNF抑制剂
    • Adalimumab
    • Etanercept
    • Infliximab

9. 系统性自体发炎性疾病治疗药物市场（依作用机转划分）

  • 白细胞介素-1阻断
  • 白细胞介素-6受体阻断
  • Janus激酶抑制
  • 肿瘤坏死因子α抑制剂

第十章 依给药途径分類的系统性自体发炎性疾病治疗市场

  • 静脉输液
  • 口服
  • 皮下注射

第十一章 系统性自体发炎性疾病治疗市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十二章 依最终使用者分類的系统性自体发炎性疾病治疗市场

  • 诊所
  • 居家照护
  • 医院
  • 专业医疗中心

第十三章 各地区系统性自体发炎性疾病治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 系统性自体发炎性疾病治疗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国系统性自体发炎性疾病治疗市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国系统性自体发炎性疾病治疗市场

第十七章：中国系统性自体发炎性疾病治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • CSL Behring LLC
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Grifols SA
  • Horizon Therapeutics plc
  • Ipsen SA
  • Johnson & Johnson（Janssen Biotech）
  • Merck & Co. Inc.
  • Novartis AG
  • Novimmune SA
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • UCB SA
Product Code: MRR-C36616F699BB

The Systemic Autoinflammatory Diseases Drug Market was valued at USD 1.04 billion in 2025 and is projected to grow to USD 1.12 billion in 2026, with a CAGR of 8.24%, reaching USD 1.82 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.04 billion
Estimated Year [2026] USD 1.12 billion
Forecast Year [2032] USD 1.82 billion
CAGR (%) 8.24%

An authoritative introduction to systemic autoinflammatory disease therapeutics, mapping current clinical challenges, diagnostic hurdles, and the strategic imperatives guiding development and stakeholder engagement

Systemic autoinflammatory diseases present an evolving therapeutic frontier defined by heterogeneous clinical phenotypes, complex diagnostic pathways, and unmet needs that span symptom control to long-term disease modification. The landscape drives an interdisciplinary set of imperatives for drug developers, clinicians, and payers: to accelerate reliable diagnostic algorithms, to refine stratified treatment approaches, and to align clinical trial endpoints with meaningful patient-centered outcomes. These factors increase the importance of integrated evidence generation throughout the life cycle of new and repurposed agents.

As translational science advances, stakeholder expectations shift toward demonstrating durable clinical benefit, favorable safety profiles in chronic use, and real-world value that supports reimbursement. Concurrently, clinical care pathways are adapting to accommodate biologics and small molecules with differing administration modalities and monitoring requirements. This dynamic requires a more sophisticated commercial playbook that integrates health economics, provider education, and patient support to enable uptake. Transitioning from theoretical efficacy to sustained clinical adoption will require coordinated efforts across regulatory science, payer dialogue, and clinical guideline development.

Consequently, organizations entering this space must prioritize cross-functional alignment, invest in evidence that resonates with specialists and generalists, and design supply chain and distribution plans that support flexible access models. In sum, the introduction to this therapeutic area highlights both the scientific progress and the strategic complexity companies must address to achieve durable clinical and commercial success.

A deep analysis of transformative scientific, regulatory, and commercial shifts altering the systemic autoinflammatory disease landscape and accelerating novel modality adoption across care pathways

Transformative shifts in the systemic autoinflammatory disease landscape are unfolding across scientific discovery, regulatory frameworks, and commercial execution. Advances in cytokine biology and the validation of discrete inflammatory pathways have repositioned targets such as interleukin-1, interleukin-6, Janus kinases, and tumor necrosis factor alpha from experimental candidates to clinically actionable mechanisms. These scientific clarifications enable more precise patient stratification and the potential for combination or sequential therapeutic regimens that address both acute flares and chronic inflammation.

Regulatory pathways are concurrently evolving to accommodate adaptive trial designs, surrogate endpoints tied to biomarker resolution, and conditional approvals that demand robust post-authorization evidence. These changes create opportunities for accelerated access but also place a premium on well-designed real-world evidence programs and proactive regulatory engagement. From a commercial standpoint, payers are increasingly focused on outcomes-based contracting and total cost of care, prompting manufacturers to demonstrate not only clinical efficacy but also durable reductions in hospitalizations, steroid use, and downstream complications.

Finally, shifts in care delivery models-such as decentralized clinical trials and digital monitoring-are reshaping patient identification and long-term follow-up. Taken together, these scientific, regulatory, and commercial inflections are catalyzing novel go-to-market architectures and collaborative partnerships aimed at shortening time-to-adoption while managing long-term value delivery.

An assessment of cumulative United States tariff impacts in 2025 on systemic autoinflammatory therapeutics supply chains, pricing dynamics, and cross-border commercial strategies for manufacturers

In 2025, cumulative tariff policy changes in the United States introduced new variables into the global supply chain environment for systemic autoinflammatory therapeutics, influencing procurement, distribution, and pricing strategies for stakeholders across the value chain. Manufacturers are reassessing sourcing footprints and supplier diversification to mitigate tariff exposure while maintaining continuity for complex biologics and sterile injectable formulations that require temperature-controlled logistics. These adjustments underscore the strategic importance of regional manufacturing capabilities and flexible contract manufacturing relationships that can absorb tariff-related cost volatility.

Payers and health systems are responding by intensifying scrutiny of total delivered cost, which includes duties and import-related fees. This heightened attention incentivizes manufacturers to present transparent cost and value narratives, to explore localized inventory strategies, and to negotiate distribution agreements that optimize landed cost without compromising product integrity. In parallel, procurement teams are increasingly evaluating the balance between onshore production premiums and the stability benefits they deliver, particularly for high-priority parenteral agents.

Moreover, tariffs can accelerate shifts toward alternative administration routes or formulations that simplify distribution complexity. These operational and commercial responses together demonstrate that tariff-driven pressures extend beyond immediate cost impacts; they refract through supply chain design, commercialization timing, and strategic choices about where to invest for resilience. Stakeholders that proactively integrate tariff scenarios into planning will better preserve launch momentum and maintain patient access amid evolving trade environments.

Key segmentation-driven insights illuminating how drug class, mechanism of action, administration route, distribution channels, and end-user settings shape therapeutic strategies and patient outcomes

Segmentation clarity provides a strategic framework to align clinical development with commercial pathways and patient needs. Examining drug class distinctions highlights that interleukin-1 inhibitors-including agents such as anakinra, canakinumab, and rilonacept-tend to focus on rapid control of autoinflammatory flares and may emphasize short-interval dosing strategies and acute care reduction. Interleukin-6 receptor blockade options like sarilumab and tocilizumab offer alternative cytokine-targeted approaches that can be positioned for persistent systemic inflammation control. Janus kinase inhibitors such as baricitinib, tofacitinib, and upadacitinib represent oral modality advantages with potential for broader systemic immunomodulation, while tumor necrosis factor inhibitors such as adalimumab, etanercept, and infliximab remain important comparators for chronic inflammatory control with extensive real-world safety data.

Mechanism of action segmentation underscores differentiation opportunities tied to interleukin-1 blockade, interleukin-6 receptor blockade, Janus kinase inhibition, and tumor necrosis factor alpha inhibition, each presenting distinct biomarker profiles and monitoring needs that influence payer and clinician acceptance. Route of administration considerations-spanning intravenous infusion, oral administration, and subcutaneous injection-drive different patient support models and adherence dynamics, with implications for site-of-care economics and patient preference.

Distribution channel and end-user segmentation further refine go-to-market approaches by recognizing the roles of hospital pharmacies, online pharmacies, and retail pharmacies in enabling access, and by acknowledging clinical settings such as clinics, home care, hospitals, and specialty centers as primary touchpoints for treatment initiation and ongoing management. Together, these segmentation lenses inform targeted clinical development decisions, differentiated messaging, and tailored access strategies that resonate with specific stakeholders.

Regional insights identifying differentiated clinical adoption patterns, payer behaviors, and regulatory nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific markets

Regional dynamics continue to shape development and commercialization strategies in distinct ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each presenting unique regulatory, payer, and clinical adoption environments. In the Americas, clinician familiarity with biologics and established specialty pharmacy infrastructures support adoption, but payer scrutiny emphasizes cost-effectiveness and real-world outcomes that demonstrate value beyond symptomatic control. Transitioning from guideline recognition to broad payer coverage requires robust health-economic evidence and stakeholder engagement that addresses both acute care savings and long-term morbidity reduction.

In Europe, Middle East & Africa, regulatory heterogeneity and varying reimbursement mechanisms necessitate region-specific evidence packages and adaptive pricing strategies. Centralized approvals in some European jurisdictions coexist with localized reimbursement assessments that prioritize comparative effectiveness and budget impact analysis. In the Middle East and Africa, infrastructure and access variability underscore the importance of partnerships that support cold-chain logistics, clinician training, and patient support mechanisms.

The Asia-Pacific region presents a spectrum ranging from highly advanced markets with rapid adoption potential to emerging markets where affordability and distribution networks are the primary constraints. Local manufacturing partnerships, tailored pricing, and culturally appropriate patient support programs often accelerate uptake. Across all regions, early alignment with regional key opinion leaders, investment in real-world evidence generation, and flexible commercial models that reflect provider and payer needs will be decisive factors in successful geographic rollouts.

Strategic company-level insights that examine competitive positioning, pipeline focus, partnership approaches, and commercialization models among leading biopharmaceutical developers

Companies operating in the systemic autoinflammatory therapeutics space are defining distinct strategic approaches across discovery, clinical development, and commercialization. Leading developers invest in differentiated science that targets validated cytokine pathways while simultaneously pursuing label-expanding indications and combination strategies to maximize clinical benefit. Competitive positioning increasingly hinges on generating head-to-head or real-world comparative evidence that clarifies relative efficacy, safety, and value versus established therapies.

Partnership strategies are also central to competitive advantage; alliances with contract manufacturing organizations, specialty pharmacy providers, and diagnostic developers enable faster scale-up and improved patient access. Firms that prioritize integrated launch models-aligning commercial analytics, medical affairs, and payer engagement early in development-are better positioned to negotiate value-based arrangements and demonstrate system-level savings.

At the same time, commercialization models are evolving toward hybrid distribution and support programs that reduce administrative friction for prescribers and patients. Organizations that strengthen their evidence generation through longitudinal observational studies and pragmatic trials add credibility in payer dialogues and can accelerate adoption. Ultimately, corporate success in this space will reflect the ability to translate mechanistic differentiation into measurable clinical outcomes, to secure pragmatic access pathways, and to execute distribution strategies that deliver consistent, patient-centered care.

Actionable recommendations for industry leaders to optimize development prioritization, commercial execution, and collaborative approaches across translational, regulatory, and market-access domains

Industry leaders can pursue several targeted actions to strengthen development, access, and long-term sustainability in systemic autoinflammatory therapeutics. First, prioritize biomarker-driven patient segmentation and adaptive trial designs that increase the probability of demonstrating clinically meaningful endpoints and facilitate regulatory dialogue. This approach shortens development cycles and yields evidence that is directly relevant to clinicians and payers. Second, invest in real-world evidence infrastructures and post-authorization studies that confirm long-term safety and health-economic benefits, enabling more compelling reimbursement propositions.

Third, design flexible commercial models that account for varied routes of administration and site-of-care preferences; these models should integrate patient support services that improve adherence and reduce administrative burdens for prescribers. Fourth, fortify supply chains through geographic diversification and strategic manufacturing partnerships to mitigate tariff and logistics risks and to preserve product integrity. Fifth, cultivate payer relationships early by co-developing outcome measures and contracting frameworks that reflect shared risk and reward.

Collectively, these recommendations emphasize the need for integrated planning across R&D, regulatory affairs, market access, and commercial operations. Adhering to these priorities will help organizations navigate complexity, accelerate responsible adoption, and ultimately deliver improved outcomes for patients living with systemic autoinflammatory conditions.

A transparent research methodology overview detailing data sources, stakeholder interviews, evidence synthesis, and analytical frameworks applied to derive strategic conclusions and insights

This research synthesizes primary and secondary evidence through a structured, reproducible methodology that balances depth with practical relevance. Data inputs include peer-reviewed literature, regulatory filings, clinical guideline statements, and anonymized real-world evidence sources, complemented by targeted stakeholder interviews with clinicians, payers, manufacturers, and supply chain experts. The evidence base was evaluated against predefined inclusion criteria to ensure contemporary relevance and clinical validity.

Analytical frameworks integrated mechanism-of-action mapping, segmentation analysis across drug class and administration routes, and scenario planning for regulatory and trade policy shifts. Qualitative insights were derived from semi-structured interviews and thematic coding to surface consensus views on unmet needs and adoption barriers, while quantitative descriptive analyses were used to characterize distribution channel dynamics and site-of-care economics. Validation steps included cross-checking interview findings against public regulatory decisions and clinical guideline updates to ensure alignment with current practice.

The methodology emphasizes transparency through documentation of assumptions, source provenance, and analytic boundaries. Where uncertainty exists, sensitivity analyses clarify alternative pathways and implications for stakeholders. This approach supports robust interpretation of findings and facilitates targeted follow-up analyses tailored to specific strategic questions.

A conclusive synthesis of strategic implications, persistent challenges, and priority actions that stakeholders should consider to advance systemic autoinflammatory disease care and commercial success

The conclusion synthesizes the strategic implications for stakeholders navigating the systemic autoinflammatory disease landscape. Scientific advances have clarified actionable targets and enabled a growing set of therapeutic options, yet durable clinical adoption depends on evidence that extends beyond controlled trials into pragmatic, real-world settings. Regulatory and reimbursement environments are evolving in ways that reward demonstrable value and adaptive evidence generation, requiring coordinated investments in post-approval data and stakeholder engagement.

Operational considerations-such as manufacturing resilience, distribution flexibility, and patient support program design-remain central to preserving access and maintaining launch momentum. Tariff and trade policy dynamics add another layer of complexity that influences sourcing decisions and landed cost calculations. From a commercial perspective, success will favor organizations that integrate mechanism-based differentiation with pragmatic distribution strategies and payer-oriented evidence programs.

Ultimately, the pathway to improved outcomes for patients and sustainable commercial performance demands cross-functional alignment, transparent value demonstration, and agile execution. Stakeholders that act on these priorities will be better equipped to deliver meaningful therapeutic advances while navigating the systemic, regulatory, and commercial challenges that characterize this therapeutic area.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Systemic Autoinflammatory Diseases Drug Market, by Drug Class

  • 8.1. Il-1 Inhibitors
    • 8.1.1. Anakinra
    • 8.1.2. Canakinumab
    • 8.1.3. Rilonacept
  • 8.2. Interleukin-6 Receptor Blockade
    • 8.2.1. Sarilumab
    • 8.2.2. Tocilizumab
  • 8.3. Jak Inhibitors
    • 8.3.1. Baricitinib
    • 8.3.2. Tofacitinib
    • 8.3.3. Upadacitinib
  • 8.4. Tnf Inhibitors
    • 8.4.1. Adalimumab
    • 8.4.2. Etanercept
    • 8.4.3. Infliximab

9. Systemic Autoinflammatory Diseases Drug Market, by Mechanism Of Action

  • 9.1. Interleukin-1 Blockade
  • 9.2. Interleukin-6 Receptor Blockade
  • 9.3. Janus Kinase Inhibition
  • 9.4. Tumor Necrosis Factor Alpha Inhibition

10. Systemic Autoinflammatory Diseases Drug Market, by Route Of Administration

  • 10.1. Intravenous Infusion
  • 10.2. Oral Administration
  • 10.3. Subcutaneous Injection

11. Systemic Autoinflammatory Diseases Drug Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Systemic Autoinflammatory Diseases Drug Market, by End User

  • 12.1. Clinics
  • 12.2. Home Care
  • 12.3. Hospitals
  • 12.4. Specialty Centers

13. Systemic Autoinflammatory Diseases Drug Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Systemic Autoinflammatory Diseases Drug Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Systemic Autoinflammatory Diseases Drug Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Systemic Autoinflammatory Diseases Drug Market

17. China Systemic Autoinflammatory Diseases Drug Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Amgen Inc.
  • 18.7. AstraZeneca PLC
  • 18.8. Biogen Inc.
  • 18.9. Bristol-Myers Squibb Company
  • 18.10. CSL Behring LLC
  • 18.11. Eli Lilly and Company
  • 18.12. GlaxoSmithKline plc
  • 18.13. Grifols SA
  • 18.14. Horizon Therapeutics plc
  • 18.15. Ipsen SA
  • 18.16. Johnson & Johnson (Janssen Biotech)
  • 18.17. Merck & Co. Inc.
  • 18.18. Novartis AG
  • 18.19. Novimmune SA
  • 18.20. Pfizer Inc.
  • 18.21. Regeneron Pharmaceuticals, Inc.
  • 18.22. Roche Holding AG
  • 18.23. Sanofi S.A.
  • 18.24. Swedish Orphan Biovitrum AB
  • 18.25. Takeda Pharmaceutical Company Limited
  • 18.26. UCB SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ANAKINRA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ANAKINRA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ANAKINRA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CANAKINUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CANAKINUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CANAKINUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RILONACEPT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RILONACEPT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RILONACEPT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SARILUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SARILUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SARILUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TOCILIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TOCILIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TOCILIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BARICITINIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BARICITINIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BARICITINIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TOFACITINIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TOFACITINIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TOFACITINIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY UPADACITINIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY UPADACITINIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY UPADACITINIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ADALIMUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ADALIMUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ETANERCEPT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ETANERCEPT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ETANERCEPT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INFLIXIMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INFLIXIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-1 BLOCKADE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-1 BLOCKADE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-1 BLOCKADE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JANUS KINASE INHIBITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JANUS KINASE INHIBITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JANUS KINASE INHIBITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTRAVENOUS INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTRAVENOUS INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 192. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 193. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 194. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 195. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 196. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 197. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 222. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 223. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 224. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 225. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 226. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 227. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 232. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 233. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 234. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 235. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 236. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 237. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)